Lipocine Inc. (NASDAQ: LPCN)
$6.50
-0.4100 ( -5.93% ) 39.5K
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Market Data
Open
$6.50
Previous close
$6.91
Volume
39.5K
Market cap
$34.23M
Day range
$6.33 - $7.10
52 week range
$2.31 - $11.79
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 68 | May 09, 2024 |
8-k | 8K-related | 16 | May 08, 2024 |
8-k | 8K-related | 16 | May 01, 2024 |
8-k | 8K-related | 58 | Apr 29, 2024 |
8-k | 8K-related | 17 | Apr 26, 2024 |
def | Proxies and info statements | 6 | Apr 23, 2024 |
8-k | 8K-related | 35 | Apr 11, 2024 |
8-k | 8K-related | 16 | Mar 28, 2024 |
8-k | 8K-related | 16 | Mar 25, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |